Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial

Xiaochen Yang, Lanping Liu, Xingjiang Xiong, Yun Zhang, Yongmei Liu, Wanqing Li, Kuiwu Yao, Jie WangTrials 2022 · DOI

This blog-style summary provides an overview of a study protocol published in the journal Trials regarding the clinical evaluation of a Traditional Chinese Medicine (TCM) formulation for hypertension.

TL;DR

Researchers have designed a randomized, double-blind, placebo-controlled trial to evaluate whether Bushen-Jiangya (BSJY) granules can effectively lower blood pressure in low-to-medium-risk hypertensive patients. Uniquely, the study integrates pharmacogenomic analysis of 20 specific genetic markers and cytokine profiling to understand why some patients respond better to this herbal treatment than others.

What Problem Does This Paper Address?

Hypertension (high blood pressure) is a global health crisis, yet control rates remain stubbornly low. While Western medicine offers several effective drug classes (like ACE inhibitors or calcium channel blockers), roughly 40% of patients do not achieve their target blood pressure on these alone.

The challenge is two-fold:

  1. Individual Variability: Genetic differences (SNPs) significantly influence how a person responds to antihypertensive drugs.
  2. The Need for Multi-Target Therapy: Hypertension is a complex systemic issue involving inflammation and organ damage.

Traditional Chinese Medicine (TCM) often uses multi-herb formulas that hit multiple biological targets. BSJY granules have shown promise in preliminary animal and small-scale human studies for protecting the heart and kidneys, but high-quality, "gold-standard" clinical evidence—especially regarding the genetic basis of its efficacy—is currently lacking.

Methods

This is a study protocol for a one-center, randomized, double-blind, placebo-controlled trial.

  • Participants: 260 volunteers with Stage I or II hypertension (low-to-medium risk) who also exhibit "kidney-yin deficiency" according to TCM diagnostics.
  • The Intervention: Participants are split 1:1 into two groups:
  • Experimental: BSJY granules + Amlodipine (a standard Western BP medication).
  • Control: Placebo granules + Amlodipine.
  • Duration: The trial lasts 8 weeks.
  • Novel Approach: Beyond standard blood pressure monitoring, the team is performing:
  • Pharmacogenomics: Testing 20 specific Single Nucleotide Polymorphisms (SNPs) known to be associated with blood pressure and drug response in Asian populations.
  • Cytokine Analysis: Measuring serum levels of pro- and anti-inflammatory markers (like TNFα, IL-6, and IL-10) to track systemic inflammation.

Datasets

As this is a clinical trial protocol, it does not use pre-existing datasets. Instead, it defines the data to be collected:

  • Electronic Case Report Forms (eCRFs): For recording all clinical observations.
  • 24-hour Ambulatory Blood Pressure Monitoring (ABPM): Providing a more granular look at BP fluctuations than a single office visit.
  • Genomic Data: Targeted sequencing of 20 specific loci/SNPs.
  • Quality of Life Data: Using the SF-36 health survey.

Key Insights and Ideas

  • Bridging Two Worlds: The study attempts to validate a traditional herbal formula (BSJY is based on the classical Liuwei Dihuang pill) using the rigorous standards of modern Western clinical trials.
  • Precision TCM: By looking at SNPs, the researchers are moving toward "Precision Traditional Chinese Medicine." They want to identify the genetic "fingerprint" of a patient who is most likely to benefit from BSJY.
  • The Multi-Herb Advantage: BSJY contains eight herbs (including Rehmannia and Eucommia bark). Table 1 in the paper details how these ingredients target different pathways: some improve insulin resistance, others reverse vascular remodeling, and others act as anti-inflammatories.
  • Focus on Early Intervention: By targeting "low-to-medium risk" patients, the study aims to find ways to prevent disease progression before severe organ damage occurs.

Key Results

Note: As a study protocol, final results are not yet available.

The authors hypothesize that the combination of BSJY and amlodipine will result in a significantly greater reduction in 24-hour average systolic and diastolic blood pressure compared to amlodipine alone. They also expect to see improved "TCM syndrome" scores (reduction in symptoms like headaches and vertigo) and a shift toward a more anti-inflammatory cytokine profile.

At the time of publication, recruitment was ongoing, with 80 patients already enrolled.

Limitations and Future Work

  • Single-Center Study: Conducting the trial at only one hospital (Guang’anmen Hospital) may limit the generalizability of the findings. The authors acknowledge that multi-center trials will be needed in the future.
  • Sample Size for Genomics: While 260 participants is robust for a clinical efficacy trial, it is relatively small for genetic studies. Detecting subtle gene-drug interactions often requires thousands of participants.
  • Targeted SNPs: The study focuses on 20 known SNPs. It is possible that other, unmeasured genetic variations are equally or more important for the response to BSJY.
  • Short Duration: An 8-week window is excellent for measuring blood pressure changes but too short to assess long-term outcomes like heart attacks or strokes.

Summary updated

Abstract

Chinese Clinical Trial Registry ChiMCTR1900002876. Registered in November 2019.
BibTeX
@inproceedings{yang2022effects,
  author = {Xiaochen Yang and Lanping Liu and Xingjiang Xiong and Yun Zhang and Yongmei Liu and Wanqing Li and Kuiwu Yao and Jie Wang},
  title = {{Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial}},
  booktitle = {Trials},
  year = {2022},
  doi = {10.1186/s13063-022-05999-2},
}
Figure